AXDX Accelerate Diagnostics, Inc.
Accelerate Diagnostics, Inc. is an in vitro diagnostics company, which engages in the provision of solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. It also focuses on developing and commercializing innovative instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens. Its products include Accelerate Pheno and Accelerate PhenoTest. The company was founded on May 26, 1982 and is headquartered in Tucson, AZ.
Company profile
Ticker
AXDX
Exchange
CEO
Lawrence L. Mehren
Employees
Incorporated in
Location
Fiscal year end
Sector
Industry (SEC)
PerkinElmer, Inc. • Waters • Illumina • Bruker • Agilent • Coherent • Fluidigm • Harvard Bioscience • Pacific Biosciences of California • Quanterix ...
Former names
Accelr8 Technology Corp
SEC CIK
Corporate docs
IRS number
841072256
AXDX stock data
()
Calendar
10 May 19
21 Jul 19
31 Dec 19
News
Company financial data Financial data
| Quarter (USD) | Mar 19 | Dec 18 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|
| Revenue | 1.75M | 1.82M | 1.36M | 1.69M | |
| Net income | -21.72M | -22.19M | -22.1M | -23.23M | |
| Diluted EPS | -0.4 | -0.41 | -0.41 | -0.43 | |
| Net profit margin | -1241% | -1218% | -1631% | -1373% | |
| Operating income | -18.82M | -19.76M | -19.37M | -20.42M | |
| Net change in cash | 9.05M | 4.64M | -5.19M | -60.04M | |
| Cash on hand | 75.31M | 66.26M | 61.62M | 66.81M | |
| Cost of revenue | 916K | 1.3M | 680K | 717K |
| Annual (USD) | Dec 18 | Dec 17 | Dec 16 | Dec 15 | |
|---|---|---|---|---|---|
| Revenue | 5.67M | 4.18M | 246K | 147K | |
| Net income | -88.33M | -64.03M | -66.37M | -45.5M | |
| Diluted EPS | -1.62 | -1.18 | -1.29 | -1.01 | |
| Net profit margin | -1558% | -1533% | -26981% | -30951% | |
| Operating income | -80.37M | -64.18M | -66.5M | -45.55M | |
| Net change in cash | 37.75M | 9.27M | -101.34M | 67.02M | |
| Cash on hand | 66.26M | 28.51M | 19.24M | 120.59M | |
| Cost of revenue | 3.19M | 1M | 0 | 0 |
Financial data from company earnings reports
Financial report summary
?Competition
Thermo Fisher Scientific • Danaher • Danaher • Luminex • Interpace Diagnostics • Bruker • OpGen • Trek • GenMark Diagnostics • T2 Biosystems
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. freshman Bad
|
|
New words:
alternative, antimicrobial, assumption, borrowing, CDC, commencement, commensurate, consultant, covered, enable, explicitly, factory, foreseeable, goal, guarantee, history, implemented, implicitly, judgment, lessen, lessor, line, mutual, pattern, penalty, rapidly, razor, reference, referred, residual, restated, ROU, sixty, slight, slightly, substantive, substitution, supplemental, terminate, termination, therapy, transition, usage, variable
Removed:
accurate, advance, analyzed, application, approval, bargain, Bulletin, bundled, capitalizing, claim, CLEARANCE, collateral, complexity, concurrently, constitute, creation, creditor, culture, dedicate, deemed, denominator, depend, doubtful, EC, eliminating, enter, establishing, evaluating, evidence, existed, existence, expiring, explicit, facilitate, failure, flexibility, flow, focused, GILTI, global, globally, governing, grace, group, grouping, heighten, impair, incomplete, innovative, insolvency, install, insurance, intended, job, larger, lead, limit, located, manufactured, maximum, milestone, monthly, multiplexed, negotiated, ninety, objective, obsolescence, October, panel, penalize, percent, permanent, persuasive, planning, positive, President, privately, progressed, Project, proportionately, provisional, ramp, raw, reduce, reduced, reduction, refinance, refine, registrant, regulatory, Relocation, renewal, repatriated, repay, repayment, requirement, revaluation, revalued, reverse, review, routine, SAB, secured, shareholder, similarly, stability, stream, suffer, sufficiently, sustained, targeting, taxable, treating, Trump, Tucson, unamortized, unexpected, viability, vulnerability, wage, working
Financial reports
10-Q
2019 Q1
Quarterly report
10 May 19
10-K
2018 FY
Annual report
1 Mar 19
10-Q
2018 Q3
Quarterly report
6 Nov 18
10-Q
2018 Q2
Quarterly report
7 Aug 18
10-Q
2018 Q1
Quarterly report
10 May 18
10-K
2017 FY
Annual report
1 Mar 18
10-Q
2017 Q3
Quarterly report
7 Nov 17
10-Q
2017 Q2
Quarterly report
7 Aug 17
10-Q
2017 Q1
Quarterly report
5 May 17
10-K
2016 FY
Annual report
28 Feb 17
Current reports
8-K
Departure of Directors or Certain Officers
15 May 19
8-K
Accelerate Diagnostics Reports First Quarter 2019 Financial Results
9 May 19
8-K
Departure of Directors or Certain Officers
27 Feb 19
8-K
Accelerate Diagnostics Reports 2018 Fourth Quarter and Full-Year Financial Results
19 Feb 19
8-K
Accelerate Diagnostics announces preliminary 2018 fourth quarter and full-year financial results
7 Jan 19
8-K
Departure of Directors or Certain Officers
28 Dec 18
8-K
Accelerate Diagnostics reports Q3 2018 financial results
6 Nov 18
8-K
Accelerate Diagnostics announces resignation of Joan Martin as Head of Europe, Middle East, and Africa
27 Sep 18
8-K
Accelerate Diagnostics reports Q2 2018 financial results
6 Aug 18
8-K
Accelerate Diagnostics reports Q1 2018 financial results
14 May 18
Registration and prospectus
S-8
Registration of securities for employees
12 Jun 18
424B5
Prospectus supplement for primary offering
10 May 17
424B5
Prospectus supplement for primary offering
8 May 17
S-3ASR
Automatic shelf registration
13 Apr 17
S-8
Registration of securities for employees
11 Aug 16
424B5
Prospectus supplement for primary offering
10 Dec 15
424B5
Prospectus supplement for primary offering
8 Dec 15
FWP
Free writing prospectus
8 Dec 15
S-8
Registration of securities for employees
7 Nov 14
D
Exempt offering of security
4 Jun 14
Proxies
DEF 14A
Definitive proxy
5 Apr 19
PRE 14A
Preliminary proxy
22 Mar 19
DEF 14A
Definitive proxy
12 Apr 18
DEF 14A
Definitive proxy
10 Apr 17
DEF 14A
Definitive proxy
1 Apr 16
DEF 14C
Information statement
11 Feb 16
PRE 14C
Preliminary information
26 Jan 16
DEF 14A
Definitive proxy
8 Apr 15
DEF 14A
Definitive proxy
15 Apr 14
PRE 14A
Preliminary proxy
3 Apr 14
Other
SD
Conflict minerals disclosure
30 May 19
SD
Conflict minerals disclosure
26 May 18
UPLOAD
Letter from SEC
31 Oct 14
CORRESP
Correspondence with SEC
24 Oct 14
UPLOAD
Letter from SEC
3 Oct 14
CORRESP
Correspondence with SEC
9 Sep 14
UPLOAD
Letter from SEC
14 Aug 14
EFFECT
Notice of effectiveness
7 Apr 14
EFFECT
Notice of effectiveness
10 Dec 13
CORRESP
Correspondence with SEC
5 Dec 13